Disruptive Technology ChannelGoogle and Genomics? It’s a More Plausible Mix Than Meets the EyeBy Tom LydonOctober 12, 2021
Disruptive Technology ChannelGilded Age of Genomics Just Getting StartedBy Tom LydonSeptember 27, 2021
Disruptive Technology ChannelGoogle Getting Into Genomics? It Already IsBy Tom LydonSeptember 8, 2021
Disruptive Technology ChannelEarly Cancer Detection: Major Opportunity for Genomics InvestorsBy Tom LydonSeptember 3, 2021
Disruptive Technology ChannelGenomics Advancements Could Aid Breast Cancer PreventionBy Tom LydonAugust 4, 2021
Disruptive Technology ChannelUnpacking the Potential of the Synthetic Biology SpaceBy Tom LydonJuly 21, 2021
Disruptive Technology ChannelThe ARKG ETF and the Intersection of All Things TechBy Tom LydonJuly 13, 2021
Disruptive Technology ChannelPlay the New Era of Gene Editing with the ARKG ETFBy Tom LydonJuly 2, 2021
Disruptive Technology ChannelNew Gene Editing Trial Results Bump the ARKG ETFBy Tom LydonJune 29, 2021
Disruptive Technology ChannelBiogen Alzheimer’s Approval Could Signal FDA’s FlexibilityBy Tom LydonJune 15, 2021
Disruptive Technology ChannelPandemic Opening the Door for Widespread Genetic TestingBy Tom LydonJune 2, 2021
Disruptive Technology ChannelA Base Hit: How Base Editing Is Changing GenomicsBy Tom LydonMay 26, 2021
Disruptive Technology ChannelHow Genomics Is Improving Cancer Screening, InvestingBy Tom LydonMay 18, 2021
Disruptive Technology ChannelIs This Ark Invest ETF a Sustainable Investing Play?By Tom LydonMay 13, 2021
Disruptive Technology ChannelAccelerating Gene Therapies? There’s an ETF for ThatBy Tom LydonMay 5, 2021
